Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
The company is stepping back in second-line breast cancer.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Giredestrant will soon become the first oral SERD to yield first-line data.
But this adds another complexity, and has camizestrant really scored a first-line win?
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.